Advancing Real-World Effectiveness Evidence for Rapid-Acting Psychotropic Interventional Drugs (RAPIDs)

The National Institute of Mental Health (NIMH) will issue a Notice of Funding Opportunity to establish a research network that evaluates rapid‑acting psychotropic interventional drugs (RAPIDs) such as ketamine, esketamine, and psilocybin. The network will generate real‑world evidence on clinical effectiveness, safety, durability, and implementation across diverse settings, informing how these treatments can be integrated into routine mental‑health care. Three cooperative‑agreement awards totaling $20 million are anticipated. • Focus on rapid‑acting psychotropic interventions for serious mental illness. • Requires development of a multi‑site research network to collect real‑world data. • Funding mechanism: Cooperative Agreement (CA) with an estimated $20 M total, three awards. • Eligible applicants include a wide range of public, nonprofit, tribal, and for‑profit entities. • Anticipated start July 1 2027; award decision expected July 1 2027.